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Uremic malnutrition is a predictor of death independent of in-
flammatory status.
Background. Several studies have pointed out the influence
of nutritional parameters and/or indices of inflammation on
morbidity and mortality. Often, these conditions coexist, and
the relative importance of poor nutritional status and chronic
inflammation in terms of predicting clinical outcomes in chronic
hemodialysis (CHD) patients has not been clarified.
Methods. We undertook a prospective cohort study analyz-
ing time-dependent changes in several established nutritional
and inflammatory markers, and their influence on mortality in
194 CHD patients (53% male, 36% white, 30% with diabetes
mellitus, mean age 55.7 ± 15.4 years) throughout a 57-month pe-
riod. Serial measurements of serum concentrations of albumin,
prealbumin, creatinine, transferrin, cholesterol, and C-reactive
protein (CRP), as well as normalized protein catabolic rate,
postdialysis weight, and phase angle and reactance by bioelec-
trical impedance analysis were performed every 3 months. Clin-
ical outcomes were simultaneously assessed using indicators of
mortality.
Results. Serum albumin, serum prealbumin, serum creatinine,
and phase angle were significant predictors of all-cause mortal-
ity, even after adjustment for serum CRP concentrations. Serum
CRP concentrations were not significantly associated with mor-
tality. Serum albumin concentrations and phase angle were also
independent predictors of cardiovascular deaths in the multi-
variate model.
Conclusion. The nutritional status of CHD patients predicts
mortality independent of concomitant presence or absence of
inflammatory response. Prevention of, and timely intervention
to treat uremic malnutrition by suitable means are necessary
independent of the presence and/or therapy of inflammation in
terms of improving clinical outcomes in CHD patients.
Uremic malnutrition and chronic inflammation are
highly prevalent in chronic hemodialysis (CHD) patients
[1, 2]. These comorbid conditions tend to coexist, and
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a number of CHD patients with elevated markers of
inflammation tend to have higher incidence of uremic
malnutrition [1]. Several studies also linked chronic in-
flammation and uremic malnutrition to clinical outcome
separately [3–7]. Presence of each condition is identified
as strong predictor of increased risk of death and hospital-
ization events. Nevertheless, there is ongoing controversy
regarding the relative importance of these 2 conditions
in terms of predicting mortality in CHD patients. Studies
have shown that the predictive ability of serum albumin is
dissipated when adjusted for the influence of C-reactive
protein (CRP) [8]. Owen et al reported contrary find-
ings, suggesting that serum albumin is a reliable indicator
even when adjusted for CRP [9], albeit the follow-up in
this particular study was limited to 6 months.
In order to clarify the relationship between uremic mal-
nutrition, chronic inflammation, and their [independent]
ability to predict mortality in CHD, we prospectively
studied 194 CHD patients over a 57-month period, evalu-
ating a broad range of nutritional markers and a marker
of inflammatory response at multiple time points, and
monitored death as a marker of long-term clinical out-
come. Our results indicate that the presence of uremic
malnutrition predicts mortality (all-cause and cardiovas-
cular) independent of the presence of inflammation in
CHD patients.
METHODS
Patients
Patients were recruited from Vanderbilt University
Outpatient Dialysis Clinic. The study period was from
January 1996 through December 2000. All prevalent
patients in February 1996, and all incident patients
thereafter (after 90 days of initiation), were asked to
participate in this study. Enrollment period was from
January 1996 to December 1999. A total of 194 pa-
tients on CHD therapy agreed to be followed and
were included in this study. All patients were dialyzed
with biocompatible membranes throughout the study
period. Patients’ routine laboratory parameters, such
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Table 1. Patient characteristics
Gender (M/F) 102 (53.1%)/92 (46.9%)
Race (W/AA) 71 (35.8%)/123 (64.2%)
Age years 55.7 ± 15.4
Etiologic disease N (%)
Diabetes mellitus 57 (29.38%)
Hypertension 36 (18.56%)
Glomerulonephritis 21 (10.82%)
Other 20 (10.31%)
Unknown 60 (30.93%)
as hemoglobin, serum phosphorus, and serum calcium
were kept within acceptable ranges through estab-
lished protocols. Recombinant human erythropoietin and
intravenous iron (Dextran) were prescribed to keep
hematocrit within the range of 33% to 36%. All patients
underwent monthly formal urea kinetic modeling during
the study period. Urea reduction ratio (URR) and Dep-
ner kinetics for Kt/V were used once a month during the
study period to assess the dose of dialysis, with a goal of
URR ≥70% and Kt/V ≥1.4. The minimum dialysis dose
prescribed at the dialysis unit was single pool Kt/V ≥1.4,
and the attending nephrologists determined the dialysis
prescription for individual patients.
The Institutional Review Board approved the study
protocol, and informed consent was obtained from study
patients. Patients’ characteristics are depicted in Table 1.
Study design
This was a prospective cohort of 194 CHD patients.
The study consisted of serial (every 3 months) measure-
ments of serum albumin, serum prealbumin, serum crea-
tinine, serum transferrin, serum total bicarbonate (tCO2),
serum CRP, normalized protein catabolic rate (nPCR),
body mass index (BMI), and the bioelectrical impedance
analysis (BIA)-derived nutritional markers phase angle
and reactance. There were no specific interventions in pa-
tient care related to the study. Mortality was recorded and
documented as “all-cause mortality,” as well as “specific-
cause” mortality (grouped as cardiovascular, infection,
and other causes).
Methods
Sample collections were completed within the first
week of each month of data analysis in a nonfasting state
before the hemodialysis session (Monday or Tuesday).
On the day of the sample collection, patients underwent
BIA at approximately 30 minutes after completion of
hemodialysis. C-reactive protein (high sensitivity) was
measured using nephelometric analysis at the Vander-
bilt University Medical Center clinical chemistry labora-
tory. The other measurements were done at a specialized
ESRD clinical and special chemistry laboratory (Spec-
tra Laboratories, San Juan, CA, USA). Serum albumin
was analyzed using bromcresol green technique. Serum
prealbumin was analyzed by an antigen-antibody com-
plex assay, and serum transferrin was analyzed by tur-
bidimetric reading (Hitachi 717; Boehringer Mannheim,
Indianapolis, IN, USA). Bioelectrical Impedance analy-
sis was performed using a hand-held device (Quantum
BIA 101 Q; RJL Systems, Clinton Township, MI, USA)
[10]. Resistance and reactance values obtained from BIA
were processed into Cyprus 1.2 software system (RJL
Systems), allowing the calculation of body composition
parameters, including phase angle and reactance.
Statistical analysis
Analyses of study results focused on estimating the as-
sociation between the continuous variables serum albu-
min, serum prealbumin, serum creatinine, serum trans-
ferrin, serum CRP, nPCR, phase angle, and reactance
with a binary outcome (mortality). The primary end point
in this study was all-cause mortality, and the secondary
end point was cardiovascular mortality. Associations be-
tween study variables at baseline with mortality were per-
formed with the generalized linear model. Multivariate
analyses of time-dependent changes in study variables
across time points, as well as tests of associations between
these changes with mortality, were completed by using
the restricted/residual maximum likelihood-based mixed
effect model to adjust the intracorrelation effect for the
patients who had multiple follow-up measurements [11,
12]. We included possible two-way interactions in this
model for testing the statistical significance of interac-
tions. The model used was selected based on Akaike’s
Information Criterion [13]. In addition to evaluating the
study variables at baseline, we also averaged these vari-
ables across all time points for each patient to obtain a
“grand mean.” With its inherent limitations, we believe
the “grand mean” is a more comprehensive representa-
tion of the study variables than the single baseline value
for an individual patient. Comparisons between patients
who survived with those who died according to the grand
mean study variables were done using the Student t test
for normally distributed data, and the Mann-Whitney
U test for non-normally distributed data. Associations of
the grand mean with all-cause mortality, as well as with
cardiovascular mortality, were tested using survival anal-
yses. These were completed with log-rank tests and pre-
sented with Kaplan-Meier tables in univariate models. All
tests of significance were two-sided, and differences were
considered statistically significant when P value was less
than 0.05. All data were expressed as mean ± SD. SAS
version 8.02 (Cary, NC, USA) was used for all analyses.
RESULTS
One hundred and ninety-four patients were included
in this study (Table 1). Throughout the study period
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Table 2. The baseline and 6-month interval levels of study parameters (mean ± SD)
Baseline M6 M12 M18 M24 M30 M36 M42 M48
Variable N = 194 N = 189 N = 174 N = 144 N = 108 N = 83 N = 66 N = 52 N = 25
Salb g/dL 3.70 ± 0.5 3.78 ± 0.4 3.81 ± 0.4 3.82 ± 0.4 3.79 ± 0.4 3.82 ± 0.4 3.80 ± 0.4 3.80 ± 0.4 3.98 ± 0.4
SCr mg/dL 9.1 ± 3.9 9.7 ± 3.7 10.2 ± 3.3 10.2 ± 3.3 10.2 ± 3.4 10.3 ± 3.3 10.4 ± 3.5 10.8 ± 3.7 11.4 ± 3.2
Spreal mg/dLa 31.4 ± 8.9 33.3 ± 9.3 33.5 ± 8.8 34.3 ± 10.0 33.5 ± 10.3 34.2 ± 9.1 32.9 ± 9.8 33.1 ± 8.3 36.3 ± 10.1
Strans mg/dL 186 ± 39 177 ± 33 176 ± 34 165 ± 32 162 ± 34 158 ± 32 163 ± 33 166 ± 35 177 ± 36
Schol mg/dL 182 ± 44 174 ± 38 170 ± 38 175 ± 40 171 ± 41 168 ± 36 169 ± 36 161 ± 38 161 ± 36
Phang degrees 5.4 ± 1.7 5.6 ± 1.8 5.4 ± 1.8 5.6 ± 2.0 5.9 ± 2.0 6.3 ± 2.0 6.0 ± 1.9 6.3 ± 1.8 6.7 ± 1.6
React ohms 50 ± 16 52 ± 16 51 ± 15 54 ± 18 57 ± 18 59 ± 16 59 ± 19 60 ± 16 62 ± 16
Pst HD wt kga 76 ± 22 76 ± 21 77 ± 20 77 ± 22 79 ± 22 81 ± 20 85 ± 20 84 ± 18 78 ± 17
CRP mg/dL 1.4 ± 2.1 1.2 ± 1.8 1.6 ± 2.4 1.8 ± 2.4 1.7 ± 2.6 2.4 ± 2.6 2.0 ± 3.2 3.8 ± 1.1 1.9 ± 2.3
NPCR g/kg/d 0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.2 1.0 ± 0.2 0.9 ± 0.2 0.9 ± 0.2 1.0 ± 0.2
Abbreviations are: Salb, serum albumin; SCr, serum creatinine; Sprealb, serum prealbumin; Strans, serum transferrin; Schol, serum cholesterol; Phang, phase angle;
React, reactance; Pst HDwt, post hemodialysis weight; CRP, serum C-reactive protein; nPCR, normalized protein catabolic rate.
aP < 0.05 for trend over 48 months.
50 patients (22 male, 28 female) died, 23 patients trans-
ferred out, 10 patients received kidney transplants, and
7 patients switched to peritoneal dialysis. Data were col-
lected until patients were censored from the study (study
period completion, transfer, transplant, or death). Mean
follow-up was 36 months (range 6–57 months). Overall
survival during the study period was 89% at 24 months,
77% at 36 months, 54% at 48 months, and 47% at
57 months. This unexpectedly high survival rate might
be due to an unintentional selection bias towards inclu-
sion of healthy subjects in the study. Causes of death were
cardiovascular for 23 patients, infectious for 15 patients,
and other causes for 9 patients. The cause of death was
unknown for 3 patients.
Baseline values of nutritional markers predict mortality
We examined the 5-year predictive power of each study
variable at baseline. Our results confirmed those previ-
ously published, in that baseline values of the nutritional
markers serum albumin, serum prealbumin, serum crea-
tinine, phase angle, and postdialysis weight significantly
and negatively predicted all-cause mortality during the
study period (P < 0.01 for all). Contrarily, CRP values at
baseline were positively associated with mortality in this
population, with a marginal statistical significance (P =
0.06).
Time-dependent changes in study variables
Mean (± SD) values of study parameters at baseline
and at 6-month intervals (up to 48 months) are depicted in
Table 2. The baseline concentration was 3.70 ± 0.48 g/dL
for serum albumin, 9.1 ± 3.9 mg/dL for serum creatinine,
31.4 ± 8.9 mg/dL for serum prealbumin, 186 ± 39 mg/dL
for serum transferrin, 5.4 ± 1.7 degrees for phase angle,
50 ± 16 ohms for reactance, and 1.4 ± 2.1 mg/dL for CRP.
Most of the study variables were stable with the exception
of slight, but statistically significant, increases in postdial-
Table 3. The mean values for each study parameter grouped
according to survivors and nonsurvivors
Survivors Nonsurvivors
CRP mg/dL 1.6 ± 1.3 1.9 ± 1.3
Salb g/dL 3.8 ± 0.3a 3.6 ± 0.3
Screat mg/dL 10.1 ± 3.3a 8.4 ± 2.4
Sprealb mg/dL 34.2 ± 7.7a 28.5 ± 6.6
Post-HD weight kg 80.1 ± 21.1a 70.2 ± 21.1
Phase angle degrees 6.0 ± 1.4a 4.4 ± 1.4
aDenotes significant difference vs. nonsurvivors.
ysis body weight and serum prealbumin concentrations
during the study period (P < 0.05 for both).
Nutritional markers are overall associated with mortality
We initially compared the overall means of study vari-
ables between survivors and nonsurvivors by averaging
all measurements for each individual patient over time,
and then averaging according to survivor status (grand
mean). Table 3 shows mean values (± SD) of study vari-
ables in survivors and nonsurvivors (all-cause mortality).
All averaged nutritional markers were significantly dif-
ferent between the 2 groups (i.e., patients who died had
lower averaged levels of serum albumin, serum creati-
nine, serum prealbumin, phase angle, reactance, and body
weight during the study period compared to patients who
survived). The inflammation marker CRP was higher in
patients who died, but the difference did not reach statis-
tical significance (1.95 ± 1.35 vs. 1.59 ± 1.30, respectively,
P > 0.05).
Patients were then grouped according to quartiles of
the “grand mean” serum concentrations of albumin, pre-
albumin, creatinine and CRP to perform univariate sur-
vival analyses. Figures 1, 2, and 3 depict Kaplan-Meier
survival tables for quartiles of serum albumin, serum pre-
albumin, and serum creatinine. As can be seen, there is
a significant difference in survival status comparing high-
est versus lowest quartile by log-rank test (P < 0.001),
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Fig. 1. Kaplan-Meier survival curves for quartiles of mean serum al-
bumin during the study period. P < 0.001 for Q4 vs. Q1, by log-rank
test.
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Fig. 2. Kaplan-Meier survival curves for quartiles of mean serum pre-
albumin during the study period. P < 0.001 for Q4 vs. Q1, by log-rank
test.
which starts to be evident after 20 months. A similar anal-
ysis with CRP showed no significant survival difference
comparing highest versus lowest quartiles of serum CRP
(Fig. 4, P = 0.275). Remarkably, patients in the lowest
quartile of both serum albumin and serum prealbumin
displayed a mortality rate of more than 20% at 2 years,
and close to 80% at 4 years of follow-up.
Changes in nutritional markers overtime predict all-cause
mortality
We looked at the predictive power of the changes in
nutritional markers over the study period by multivari-
ate mixed model, including serum concentrations of al-
bumin, prealbumin, creatinine, and CRP, in addition to
case-mix adjustments (age, gender, race). We found that
changes in serum albumin, serum creatinine, and serum
prealbumin over time were strong predictors of all-cause
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Fig. 3. Kaplan-Meier survival curves for quartiles of mean serum cre-
atinine during the study period. P < 0.001 for Q4 vs. Q1, by log-rank
test.
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Fig. 4. Kaplan-Meier survival curves for quartiles of mean CRP during
the study period. P = 0.275 for Q4 vs. Q1, by log-rank test.
mortality even after CRP (with and without log trans-
formation) was incorporated into the model (P < 0.01
for all). When analyzing the same group of covariates by
time-dependent Cox regression, serum albumin, preal-
bumin, and creatinine were still strong predictors, with
serum prealbumin at a lesser extent (P = 0.06). Table 4
depicts the parameter estimates of the changes with
hazard ratios and level of significance of each variable.
Based on these estimates, in practical terms, a decrease of
0.31 g/dL in serum albumin concentration [i.e., the differ-
ence from the means in fourth (4.17 g/dL) and third quar-
tiles (3.86 g/dL)] was associated with an increased relative
risk of death of 6.3. Likewise, a decrease in serum albu-
min of 0.28 g/dL, which is the difference from the means
in third (3.86 g/dL) and second quartiles (3.58 g/dL), was
associated with a relative risk of death of 8.1 (Fig. 5).
Similar strong associations between decreases in serum
prealbumin and increased risk of death were observed
(data not shown).
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Table 4. Relationship between changes in study variables over the
study period with mortality
Parameter Standard Hazard
Variable estimate error ratio P value
Albumin −29.12 14.33 0.000 0.042
Prealbumin −1.71 0.93 0.181 0.068
Phase angle −1.93 2.45 0.145 0.448
Creatinine −6.15 2.65 0.002 0.020
CRP 1.15 1.14 3.174 0.309
Age 0.059 0.02 1.060 0.001
Gender −0.103 0.39 0.902 0.790
Race 0.430 0.41 1.537 0.290
Bolded numbers denote P < 0.15 in multivariate time-dependent Cox
regression model.
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Fig. 5. Relative risk for all-cause death according to quartiles of mean
serum albumin during the study period. Patients with serum albumin
concentrations ≤3.18 g/dL were 26 times more likely to die of any cause
compared with those with serum albumin concentrations ≥4.17 g/dL.
P < 0.001 Q2, 3, and 4 vs. Q1.
Nutritional markers are predictors of cardiovascular
mortality
Data were also analyzed according to specific causes of
death. There were a total of 23 cardiovascular deaths dur-
ing the study period. In univariate analyses, lower mean
levels of serum albumin, serum prealbumin, serum crea-
tinine, and phase angle at baseline were significant pre-
dictors of higher risks of cardiovascular mortality. Mean
CRP (with and without log transformation) concentra-
tions did not predict cardiovascular death in our study.
In multivariate models including grand mean values
of serum albumin, serum prealbumin, serum creatinine,
phase angle, CRP, and case-mix adjustment, serum albu-
min and phase angle were the only significant predictors
of cardiovascular mortality, with phase angle displaying
a very strong predictive power. As shown in Figure 6, a
CHD patient in the lowest tertile for phase angle (mean
3.7 degrees) throughout the study period was 20 times
more likely to die due a cardiovascular cause compared
with a patient in the highest tertile (mean of 7.5 degrees).
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Fig. 6. Relative risk for cardiovascular death according to tertiles of
mean phase angle during the study period. Patients with phase angle
≤4.8 degrees were 20 times more likely to die of cardiovascular compli-
cations compared with those with phase angle ≥6.5 degrees. P < 0.001
T3 vs. T1.
DISCUSSION
Markers of uremic malnutrition and inflammation not
only tend to coexist, but are often inversely correlated in
CHD patients [14, 15]. This observation has led investi-
gators to believe that the nutritional markers are rather
markers of overall health status with systemic inflam-
matory response syndrome (SIRS) as the primary driv-
ing force for changes in nutritional markers, resulting in
problems with interpretation of the clinical relevance and
importance of low levels of nutritional markers. Never-
theless, there are data to suggest that higher levels of DPI
result in improvement in nutritional markers in the pres-
ence of inflammation [16]. This prospective cohort was
designed to test the hypothesis that uremic malnutrition
is associated with mortality in CHD patients independent
of the presence of inflammatory response. The design was
strengthened by utilization of a comprehensive array of
nutritional markers along with multiple measurements
of these variables over a relatively long study period. We
were able to show that several nutritional markers, in-
dependent of the presence or absence of inflammatory
response, were associated with mortality in our patient
population. The implication of our study is that, although
at times nutritional parameters such as serum albumin
and serum prealbumin are indeed depressed in the pres-
ence of inflammation, most often they primarily reflect
nutritional status, and that their association with ad-
verse outcomes in relation to uremic malnutrition re-
mains strong.
Several potential explanations can be speculated to in-
terpret our results. It is most likely that nutritional sta-
tus worsens over time due to multiple catabolic factors,
including acute-phase response and associated morbid
events, which ultimately results in increased risk of mor-
tality in CHD patients [17]. Equally important, Kaysen et
al [16] have shown that higher protein intake attenuates
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the effects of inflammation. Further, poor nutritional sta-
tus can also play a permissive role for the development
of infections, which also activates inflammatory reaction.
Therefore, poor nutritional status may also accelerate the
adverse effects of inflammation on clinical outcomes. Nu-
tritional support has been shown to improve protein and
energy homeostasis, nutritional markers, and survival in
chronic hemodialysis patients with low albumin levels,
suggesting that poor nutritional status is an entity beyond
the consequence of inflammation alone [18–20].
Our study has several unique features compared to
previously published studies evaluating the relationship
between nutritional status, inflammation, and clinical out-
come. These earlier studies almost exclusively relied on
a one-time assessment of study variables with subse-
quent follow-up of clinical outcome. Among these, sev-
eral studies indicated that the predictive ability of serum
albumin as a nutritional marker on clinical outcome is
dissipated when adjusted for the influence of CRP, a
well-established marker of inflammation [8]. On the other
hand, findings by Owen et al suggest that serum albumin
is a reliable indicator of nutritional status even when ad-
justed for CRP, albeit follow-up was limited to 6 months
in this study [9]. In addition to utilization of a single point
measurement of the predictive variables, these studies ex-
amined the limited number of nutritional markers. In the
present study, we used a wide combination of nutritional
markers along with an inflammation marker (CRP) over
a period of 57 months (4.7 years). For example, the as-
sociations between serum albumin and clinical outcome
were confirmed with measurements of serum prealbu-
min, serum creatinine, and phase angle, all of which have
been suggested as excellent markers of nutritional status
in CHD patients [4, 21]. Furthermore, low levels of both
serum albumin and phase angle have been independently
associated with higher risk of death in CHD patients
[4, 22].
Another important characteristic of our study is the
sequential assessment of study variables over the follow-
up period. The importance of trends in clinically relevant
markers is emphasized by a recent study by Pifer et al [23],
where decreases in serum albumin and creatinine over 6
months are associated with increased risk of death. The
present study provides information on time-dependent
changes in nutritional parameters in association with a
well-established inflammatory marker in terms of pre-
dicting mortality. Further, the availability of sequential
measurements of CRP provides a reasonable approach
to overcome the variability associated with this marker
[24].
An interesting finding of this study is that we were only
able to find a significant relationship between all-cause
mortality and inflammation using baseline measurements
of CRP. This finding is consistent with recently published
studies [25–27]. On the other hand, mean CRP concen-
trations throughout the study period, as well as changes in
CRP over time, did not predict all-cause mortality, both
in univariate and multivariate analyses. While the expla-
nation of this finding is not clear, there are several pos-
sible reasons. CRP is a short-lived acute-phase protein
and may not be the ideal inflammatory marker for long-
term clinical outcome. In this respect, a recent report by
Kaysen et al [28] reported more stable associations be-
tween 2 long-lived inflammatory markers and serum
albumin. Another possible explanation is that CRP con-
centrations are highly skewed. While our results were not
different even with the use of log transformation of CRP, a
categorical analysis using certain cut-off values may pro-
vide alternative results [25]. Clearly, further studies with
potentially larger sample sizes are needed to elucidate
the relationship between chronic inflammation and long-
term outcome in CHD patients, especially if CRP is used
as the primary variable.
In this study, we also analyzed our results with re-
gard to specific causes of mortality. Recent cross-sectional
prospective studies suggested a link between the extent
of inflammation and cardiovascular outcomes in CHD
patients [7]. The direct effects of chronic inflammation
on the progression of cardiovascular disease, especially
atherosclerotic coronary artery disease, are well docu-
mented, and atherosclerosis is considered as an inflamma-
tory disease [29]. In spite of these observations, we were
not able to find a significant correlation between CRP
and cardiovascular deaths in our study population. While
this finding is somewhat unexpected and warrants further
larger-scale studies, the analysis revealed an intriguing as-
sociation between nutritional markers and cardiovascu-
lar mortality in our patient population. Specifically, phase
angle and serum albumin displayed significant associa-
tions with cardiovascular death. These findings are con-
sistent with the clinical observations in cross-sectional
studies that hypoalbuminemia correlates with cardiovas-
cular mortality in ESRD patients [30]. Our results suggest
that serum albumin as a measure of nutritional status is
associated with cardiovascular outcomes, rather than as
a marker of inflammation.
In spite of the intriguing results that are presented, one
should also consider potential limitations of this study.
This study is based on a relatively small sample size, and
represents a single practice, limiting generalizability of
findings. We measured only one inflammatory marker
and thus, our findings related to inflammation cannot be
extrapolated to other markers. Furthermore, the present
study did not assess baseline cardiac risks factors such
as atherosclerosis or left ventricular hypertrophy, factors
that might have affected mortality independently from
the nutritional markers examined and accounted for the
differences in mortality observed. Finally, this is an obser-
vational study without manipulation of exposure factors
(nutrition and inflammation) and, therefore, no definitive
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cause and effect relationship can be derived. The findings
of the current study provide stimulating data that should
lead to large-scale, prospective, randomized studies that
evaluate nutritional and anti-inflammatory interventions
in CHD patients aimed at improving clinical outcome.
CONCLUSION
We report that uremic malnutrition robustly predicts
mortality independent of concomitant presence of in-
flammatory response. Based on our findings, we con-
clude that proper preventive and/or therapeutic measures
should be employed to fight uremic malnutrition, regard-
less of the inflammatory status. Overall, comprehensive
long-term assessments, prevention of uremic malnutri-
tion by suitable means, and timely intervention to treat
poor nutritional status and inflammation are imperative
in terms of improving clinical outcome in CHD patients.
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